Publications

Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.

* denotes publications from the CTD2 initiative that are results of intra-Network collaborations

 

CTD²
September 01, 2018
Leukemia

Studies conducted by CTD2 scientists at Oregon Health and Science University have shown that combined inhibition of JAK1/2 and BCL2 as a potential therapeutic option for acute myeloid leukemia (AML) patients.

CTD²
August 13, 2018
Nature Cell Biology

CTD2 researchers at UCSF showed that SHP2, a non-receptor protein tyrosine phosphatase, could be a potential molecular target in cancers driven by oncogenic mutants of RAS/MAPK pathway.

CTD²
August 13, 2018
Journal of Clinical Pathology

Review on the role of CDK12 as a clinical biomarker and as a potential therapeutic target for cancer therapy.

CTD²
August 08, 2018
Trends in Cancer

A review article on using the patient-derived cancer models for the identification of targets to overcome roadblocks of precision oncology.

CTD²
August 01, 2018
Cold Spring Harbor Perspectives in Medicine
CTD²
July 30, 2018
eLife

Genome-scale open reading frame screen identifies RNA binding proteins, QK1 and RBFOX1, regulate the alternate splicing of actin binding protein, FLNB. The skipping of FLNB exon 30 is associated with the transition to mesenchymal- and stem-like cell states in breast cancer pathogenesis.

CTD²
July 19, 2018
Molecular Cell

Scientists at DFCI demonstrated that binding of transcription factor, ERG, to chromatin remodeling complex, BAF, is essential to facilitate basal-to-luminal transition, a hallmark of prostate oncogenesis.

Pages

CSVXML